US EditionNew three-drug combination could help women with aggressive breast cancer live longer, study suggests
- Final results from the INAVO120 trial, involving 325 breast cancer patients from 28 countries, were presented at the ASCO 2025 meeting in Chicago by a team based in London’s leading cancer research center.
- The study tested a new three-drug combination against HR+, HER2-, PIK3CA-mutated breast cancer that had progressed during or soon after hormone therapy.
- The triplet therapy of inavolisib, palbociclib, and fulvestrant improved median overall survival to 34 months versus 27 months for placebo and delayed chemotherapy by nearly two years.
- Lead author Nick Turner reported a 33% reduction in death risk with manageable side effects, though grade 3/4 adverse events occurred in 90.7% of treated patients.
- Experts called the findings a significant breakthrough that could become the new standard if licensed by UK regulators, offering longer survival and quality of life for affected patients.
Insights by Ground AI
Does this summary seem wrong?
25 Articles
25 Articles
All
Left
2
Center
4
Right
1
A new treatment halves the risk of progression or even death due to some form of breast cancer that has not seen significant therapeutic progress in more than 10 years, according to a study published on Monday.
·Montreal, Canada
Read Full Article
Evening StandardReposted by 
perspectivemedia.com
perspectivemedia.comThree-drug therapy helps women with aggressive breast cancer live longer – trial
The treatment could also delay the need for gruelling chemotherapy, according to the trial.
·London, United Kingdom
Read Full Article
MedPage TodayReposted by 
Anti-Aging, Acupuncture and Health News
Anti-Aging, Acupuncture and Health NewsSurvival Win With Inavolisib-Based Triplet in PIK3CA-Mutated Breast Cancer
(MedPage Today) -- CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, endocrine-resistant disease...
·New York, United States
Read Full ArticleCoverage Details
Total News Sources25
Leaning Left2Leaning Right1Center4Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 29%
C 57%
14%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
